Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Community Exercise for Fall Risk in PD [NA]
A completed clinical trial evaluating community exercise to reduce fall risk in Parkinson disease patients; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: Selegiline to Zelapar Switch Study in Parkinson Disease Patients [Phase 4]
Phase 4 clinical trial update evaluating a switch from selegiline to Zelapar in Parkinson's disease patients has completed with results post…
-
FDA approval · 2023-07-26FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for pramipexole dihydrochloride from Torrent Pharmaceuticals Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease [Phase 1, Phase 2]
Phase 1/2 clinical trial updates reporting multiple N-of-1 trials of intermittent hypoxia therapy in Parkinson's disease.
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: A 6-month Study to Evaluate Sulforaphane Effects in PD Patients [Phase 2]
A Phase 2 clinical trial evaluating sulforaphane effects in patients with Parkinson disease is ongoing, with status not disclosed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-07-03FDA Approved: BENZTROPINE MESYLATE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for benztropine mesylate, submitted by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Robotic Walking Device to Improve Mobility in Parkinson's Disease [NA]
A completed clinical trial evaluating a robotic walking device to improve mobility in Parkinson's disease; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-06-12Clinical Trial Update: Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
A completed clinical trial update assessing tele-health outcomes in multiyear extensions of Parkinson disease trials, with results posted in…
-
FDA approval · 2023-06-07FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Pramipexole dihydrochloride from Macleods Pharmaceuticals Limited under ANDA202164.
-
FDA approval · 2023-06-07FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for a generic pramipexole dihydrochloride product from Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations [Phase 3]
Open-label extension study update assessing safety and clinical utility of IPX203 for Parkinson's disease with motor fluctuations (Phase 3) …
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) [Phase 2]
A Phase 2 study evaluated the safety and tolerability of SAGE-718 in participants with Parkinson's disease and mild cognitive impairment (PD…
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD [Phase 4]
Phase 4 trial evaluating add-on Opicapone 50 mg or extra L-DOPA 100 mg for wearing-off in Parkinson disease has completed.
-
FDA approval · 2023-05-31FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for Pramipexole Dihydrochloride from Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2023-05-30Clinical Trial Update: Voice Treatment for Parkinson's Disease [NA]
A completed clinical trial from University of Massachusetts on a voice treatment for idiopathic Parkinson disease with posted results.
-
FDA approval · 2023-05-26FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE — Supplemental Application (Vitruvias Therapeutics, Inc.)
The FDA approved a supplemental application to market an extended-release formulation of pramipexole dihydrochloride by Vitruvias Therapeuti…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180) [Phase 2]
A Phase 2 clinical trial update examining relationships between neuropsychological testing and imaging modalities in Alzheimer and Parkinson…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease [Phase 3]
A Phase 3 clinical trial evaluating continuous apomorphine infusion for cognitive and neuropsychological outcomes in Parkinson's disease has…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Body Weight Gain, Parkinson, Subthalamic Stimulation [Phase 2]
Phase 2 clinical trial update related to body weight gain in Parkinson's disease with subthalamic stimulation.
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: Effect of Safinamide on Parkinson's Disease Related Chronic Pain [Phase 4]
Phase 4 clinical trial investigating the effect of safinamide on Parkinson's disease-related chronic pain has completed with results posted.
-
FDA approval · 2023-05-10FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark Pharmaceuticals' supplemental application for pramipexole dihydrochloride (generic).
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: GRoningen Early-PD Ambroxol Treatment [Phase 2, Phase 3]
Clinical trial update for Ambroxol treatment in Parkinson's disease (Phase 2/3) sponsored by University Medical Center Groningen.
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate [Phase 4]
Phase 4 trial update evaluating sodium oxybate for REM Sleep Behavior Disorder with Parkinson's disease; study completed with results posted…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: [18F]MC225-PET in Neurodegenerative Disease [Phase 1, Phase 2]
Early-phase trial update for [18F]MC225-PET imaging in neurodegenerative diseases, including Alzheimer’s disease and related conditions (Pha…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Hypoestes Rosea Powder in Parkinson's disease has completed.